Shares of ABIVAX Société Anonyme (NASDAQ:ABVX - Get Free Report) saw unusually-strong trading volume on Thursday . Approximately 363,981 shares traded hands during trading, an increase of 286% from the previous session's volume of 94,201 shares.The stock last traded at $10.50 and had previously closed at $10.28.
Analyst Upgrades and Downgrades
Separately, Laidlaw started coverage on ABIVAX Société Anonyme in a report on Monday, July 29th. They set a "buy" rating and a $48.00 target price on the stock. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $36.50.
Check Out Our Latest Stock Analysis on ABIVAX Société Anonyme
ABIVAX Société Anonyme Stock Up 1.7 %
The firm has a 50 day simple moving average of $11.12 and a two-hundred day simple moving average of $12.71.
Hedge Funds Weigh In On ABIVAX Société Anonyme
Hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets acquired a new position in ABIVAX Société Anonyme in the first quarter valued at about $81,000. Capstone Investment Advisors LLC increased its holdings in shares of ABIVAX Société Anonyme by 9.0% in the first quarter. Capstone Investment Advisors LLC now owns 62,966 shares of the company's stock worth $900,000 after acquiring an additional 5,199 shares in the last quarter. Kennedy Capital Management LLC increased its holdings in shares of ABIVAX Société Anonyme by 35.3% in the first quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company's stock worth $1,718,000 after acquiring an additional 31,331 shares in the last quarter. Finally, Janus Henderson Group PLC increased its holdings in shares of ABIVAX Société Anonyme by 18.2% in the first quarter. Janus Henderson Group PLC now owns 851,839 shares of the company's stock worth $12,113,000 after acquiring an additional 131,414 shares in the last quarter. Institutional investors and hedge funds own 47.91% of the company's stock.
About ABIVAX Société Anonyme
(
Get Free Report)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
Featured Articles
Before you consider ABIVAX Société Anonyme, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ABIVAX Société Anonyme wasn't on the list.
While ABIVAX Société Anonyme currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
